This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
395
Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
Darifenacin tablets 7,5 mg or 15 mg once daily
Behavioral Modification Programme for symptoms of overactive bladder
Change from baseline in average number of urinations per patient per day at Week 12
Change from baseline in average number of urination episodes per patient per day at Week 2, Week 6
Change from baseline in average number of urge urinary incontinence episodes, urgency episodes, incontinence pads, and nocturnal urinations per day measured at Weeks 2, 6, 12
Quality of Life (baseline, Week 6, Week 12)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alabama Research Center
Birmingham, Alabama, United States
Quality of Life Medical & Research
Tucson, Arizona, United States
UCLA - Urology Sciences Research Foundation
Culver City, California, United States
San Diego Center for Urology Care
La Mesa, California, United States
Orange County Urology Associates
Laguna Woods, California, United States
Atlantic Urology Medical Group
Long Beach, California, United States
California Professional Research
Newport Beach, California, United States
Private Practice
North Hollywood, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Encompass Clinical Research
Spring Valley, California, United States
...and 57 more locations